【摘要】 目的:评价水飞蓟宾-卵磷脂复合物对水飞蓟素胶囊的相对生物利用度。方法:选择22例20～40岁健康成年男性受试者,随机分为两组,自身前后交叉依次口服水飞蓟宾-卵磷脂复合物胶囊8粒（相当于水飞蓟宾280mg）和水飞蓟素胶囊2粒（相当于水飞蓟素280 mg,含水飞蓟宾112 mg）,应用高效液相色谱法测定各受试者给药后不同时间点的血药浓度,并用3P97软件计算药动学参数。结果:水飞蓟宾-卵磷脂复合物和水飞蓟素胶囊的实测T_max分别为（1．53±0．68）和（1．51±0．84）h;实测C_max分别为（3525．2±1852．1）和（412．0±241．1） ng·mL^-1;梯形法计算AUC_0～11h分别为（5064．1±1881．6）和（842．0±327．3）ng·h·mL^-1;t_1/2β分别为（2．41±0．61）和（2．30±0．62）h。经统计学分析,两者的AUC_0～11h和C_max有显著性差异（P＜0．05）。水飞蓟宾-卵磷脂复合物对于水飞蓟素胶囊的相对生物利用度为（270．4±139．6）%。结论:水飞蓟宾-卵磷脂复合物的生物利用度优于水飞蓟素胶囊。更多还原

【Abstract】 Objective:To assess the relative bioavailability of silybin-phosphatidylcholine com- pound （SPC） versus silymarin capsules （SC）.Methods:22 Chinese healthy male volunteers were ran- domized to receive a single oral crossover dose of SPC （8 capsules equivalent to 280 mg silybin） or sily- marin capsules （2 capsules equivalent to 280 mg silymarin or 112 mg silybin）.The plasma silybin con- centrations at certain timepoints after the administration of the two formulations were measured by HPLC. The pharmacokinetics parameters of SPC and SC were as follows:T_max （1.53±0.68） vs.（1.51±0.84）h,C_max（3525.2±1852.1）vs.（412.0±241.1）ng·mL^-1,AUC_0～11h（5064.1±1881.6）vs. （842.0±327.3）ng·h·mL^-1 and t_1/2β（2.41±0.61）vs.（2.30±0.62）h;the P values of these parameters were significantly different.The relative bioavailability of SPC was （270.4±139.6）%. Conclusion:The bioavailability of silibinin-phosphatidylcholine compound is superior to silymarin capsules.更多还原